United Therapeutics Stock Forecast for 2023 - 2025 - 2030

Updated on 02/04/2023

Stock Rating
12
Price Target
$295.00
Consensus
Outperform
Upside
16.69%
Analysts
4
Stock Rating
12
Upside
16.69%
Analysts
4
Price Target
$295.00

United Therapeutics Stock Forecast and Price Target

United Therapeutics's stock is projected to advance by 16.69% from the previous closing price if it reaches the average target of $295.00 by the year's end, as four reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $375.00 and a low-end estimate of $150.00. If you're looking for information on United Therapeutics stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

$295.00

16.69% Upside

Outperform
Outperform

United Therapeutics Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, United Therapeutics's Price has grown, moving from $105.20 to $124.06 – an increase of 17.93%. For the following year, the 0 analysts predict that United Therapeutics's Fair Value will drop by 7.00%, reaching $115.38. In 2030, the professionals' prediction is that UTHR's Fair Value will decrease by 6.43%, reaching $116.08.

2022 Fair Value Forecast
$115.38
2023 Fair Value Forecast
$112.22
2024 Fair Value Forecast
$114.13
2025 Fair Value Forecast
$117.42
2026 Fair Value Forecast
$116.77
2027 Fair Value Forecast
$115.25
2028 Fair Value Forecast
$114.89
2029 Fair Value Forecast
$115.73
2030 Fair Value Forecast
$116.08
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
PFE Stock Forecast Pfizer Inc Outperform 3
$44.06 $53.97 19.50%
NOVN Stock Forecast Novartis Hold 10
CHF85.77 CHF103.75 9.89%
AMGN Stock Forecast Amgen Inc Hold 7
$245.17 $268.00 13.39%
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$84.50 $87.30 4.14%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$722.13 $796.73 8.29%

United Therapeutics Revenue Forecast for 2023 - 2025 - 2030

In the last two years, United Therapeutics's Revenue has grown, moving from $1.45B to $1.69B – an increase of 16.34%. For the following year, the 0 analysts predict that United Therapeutics's Revenue will drop by 8.78%, reaching $1.54B. In 2030, the professionals' prediction is that UTHR's Revenue will decrease by 8.13%, reaching $1.55B.

2022 Rev Forecast
$1.54B
2023 Rev Forecast
$1.51B
2024 Rev Forecast
$1.51B
2025 Rev Forecast
$1.57B
2026 Rev Forecast
$1.56B
2027 Rev Forecast
$1.54B
2028 Rev Forecast
$1.53B
2029 Rev Forecast
$1.54B
2030 Rev Forecast
$1.55B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 16
$301.02 $323.74 8.30%
GSK Stock Forecast GSK Hold 16
£1.44k £16.95 -98.88%
CE Stock Forecast Celanese Outperform 13
$125.45 $125.00 -0.76%

United Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

United Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Free Cash Flow for United Therapeutics has grown by 264.45%, going from $-290.30M to $477.40M. According to the 0 analysts polled, in the next year, United Therapeutics's Free Cash Flow will fall by 16.65%, reaching $397.91M. By 2030, professionals believe that United Therapeutics's Free Cash Flow will have decreased by 12.91%, falling to $415.75M.

2022 FCF Forecast
$0.40B
2023 FCF Forecast
$0.30B
2024 FCF Forecast
$0.40B
2025 FCF Forecast
$0.43B
2026 FCF Forecast
$0.43B
2027 FCF Forecast
$0.39B
2028 FCF Forecast
$0.39B
2029 FCF Forecast
$0.41B
2030 FCF Forecast
$0.42B

United Therapeutics Net Income Forecast for 2023 - 2025 - 2030

United Therapeutics's Net Income has seen growth In the last two years, going from $-104.50M to $475.80M – a gain of 555.31% The next year, 0 experts forecast that United Therapeutics's Net Income will decrease by 34.63%, reaching $311.01M. In 2030, professionals predict that United Therapeutics's Net Income will decrease by 26.33%, reaching $350.51M.

2022 NI Forecast
$0.31B
2023 NI Forecast
$0.25B
2024 NI Forecast
$0.32B
2025 NI Forecast
$0.38B
2026 NI Forecast
$0.36B
2027 NI Forecast
$0.32B
2028 NI Forecast
$0.32B
2029 NI Forecast
$0.34B
2030 NI Forecast
$0.35B

United Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

United Therapeutics's EBITDA has grown in the last two years, jumping from $-131.70M to $736.80M – an increase of 659.45%. For the next year, 0 analysts project United Therapeutics's EBITDA to drop by 48.86%, reaching $376.77M. By 2030, professionals believe that United Therapeutics's EBITDA will decrease by 33.54%, reaching $489.64M – a concerning trend for the company.

2022 EBITDA Forecast
$0.38B
2023 EBITDA Forecast
$0.33B
2024 EBITDA Forecast
$0.44B
2025 EBITDA Forecast
$0.56B
2026 EBITDA Forecast
$0.50B
2027 EBITDA Forecast
$0.44B
2028 EBITDA Forecast
$0.45B
2029 EBITDA Forecast
$0.48B
2030 EBITDA Forecast
$0.49B

United Therapeutics EBIT Forecast for 2023 - 2025 - 2030

In the last two years, United Therapeutics's EBIT has increased by 486.77%, going from $-177.60M to $686.90M. According to 0 prominent analysts, United Therapeutics's EBIT will fall by 52.66% in the next year, reaching $325.20M. By 2030, professionals believe that United Therapeutics's EBIT will decrease by 34.69%, reaching $448.62M – a concerning trend for the company.

2022 EBIT Forecast
$0.33B
2023 EBIT Forecast
$0.29B
2024 EBIT Forecast
$0.40B
2025 EBIT Forecast
$0.52B
2026 EBIT Forecast
$0.46B
2027 EBIT Forecast
$0.40B
2028 EBIT Forecast
$0.41B
2029 EBIT Forecast
$0.44B
2030 EBIT Forecast
$0.45B

United Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, United Therapeutics's EPS has grown, moving from $12.94 to $15.26 – an increase of 17.93%. For the following year, the 0 analysts predict that United Therapeutics's EPS will drop by 7.00%, reaching $14.19. In 2030, the professionals' prediction is that UTHR's EPS will decrease by 6.43%, reaching $14.28.

2022 EPS Forecast
$14.19
2023 EPS Forecast
$13.80
2024 EPS Forecast
$14.04
2025 EPS Forecast
$14.44
2026 EPS Forecast
$14.36
2027 EPS Forecast
$14.18
2028 EPS Forecast
$14.13
2029 EPS Forecast
$14.23
2030 EPS Forecast
$14.28